The Breast Oncology Program (Program) is comprised of 39 Program Members from 13 different UCSF departments. The Program supports and stimulates basic, clinical, and population research in breast cancer and facilitates the translation of these findings into improved cancer management and control. The Program's themes are as follows: (1) epidemiology and etiology;(2) cancer prevention, risk models, and early detection;(3) genetics and biology of cancer progression;(4) new therapeutic targets and approaches;and (5) outreach, clinical care delivery, and outcomes. Research in the Program is supported by the Bay Area Breast Cancer SPORE, eight large multi-disciplinary, multi-institutional projects that support work in one or more themes, a multi-campus University of California Office of the President sponsored ATHENA Breast Health Network integrating clinical care and research by numerous individual investigator-initiated grants. Since the last competitive renewal much effort has been dedicated towards investigator initiated therapeutic trials, innovative companion diagnostic clinical trials, testing new radiation oncology treatment delivery systems including correlative science, as well as establishing a CLIA-compliant testing laboratory and an integrative bioinformatics and IT infrastructure. The Program has become more cohesive, has a high level of interaction that has led to new grant funding with joint program and project leaders and co-investigators across disciplines. Interactions between Program members are encouraged in several discussion forums, including a weekly multidisciplinary seminar, an annual retreat, a weekly tumor board, a bi-weekly breast site study review meeting, a monthly community forum, and a patient-physician management discussion series. The Program has $22,189,900 total peer-reviewed support for the last budget year. The Program has 17% intra-programmatic and 17% inter-programmatic publications.
| Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131: |
| Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228 |
| Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
| Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
| Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
| Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
| An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
| Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
| Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
| An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
Showing the most recent 10 out of 192 publications
